Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

By B. Ference, Wonsuk Yoo, I. Alesh, N. Mahajan, K. Mirowska, Abhishek Mewada, J. Kahn, L. Afonso, K. Williams, J. Flack. Journal of the American College of Cardiology, 2012

843 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pediatrics, Perinatology and Child Health, Surgery

View Paper: https://www.semanticscholar.org/paper/9404977ba3d5ee012c8e1ffc5c5cc8e516213dac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. Marja-Riitta Taskinen
3. George Davey Smith
4. S. Daniels
5. S. Grundy
6. J. Bowden
7. Alberico L. Catapano
8. Rhian M. Touyz

In Pediatrics, Perinatology and Child Health

1. J. Bowden
2. Gibran Hemani
3. I. Graham
4. George Davey Smith
5. S. Daniels
6. Stephen Burgess
7. S. Thompson
8. Deborah Lawlor

In Surgery

1. I. Graham
2. Marja-Riitta Taskinen
3. George Davey Smith
4. S. Grundy
5. J. Bowden
6. Alberico L. Catapano
7. Ulrich Laufs

Citations in the corpus

• Evaluating the potential role of pleiotropy in Mendelian randomization studies (2018, background): “The more SNPs that satisfy this expectation, the less likely it is that the SNP-outcome associations are arising simply because of horizontal pleiotropy (or distinct causal variants) (48).”
• Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets (2016, methodology): “In the analyses, we excluded SNPs in LD with the top cis -eQTL at r 2 >0.9 because SNPs in almost perfect LD with the top cis -eQTL are not informative for the HEIDI test.”
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Furthermore, Mendelian randomization studies have demonstrated that long-term exposure to lower LDL-C levels is associated with a much lower risk of CV events as compared with shorter-term exposure to lower LDL-C (as achieved, for example, in randomized trials).(48,52) These data provide strong supp”
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, background): “What is not known is whether achieving the same level of lipid lowering with medications over decades will offer the same protective effects as observed in individuals with lifelong lower cholesterol levels secondary to a genetic mutation.(275)”